Navigation Links
SRI International Completes Biosciences Facility Expansion in Shenandoah Valley, Virginia

MENLO PARK, Calif., Oct. 24, 2013 /PRNewswire/ -- SRI International has completed the final stage of expansion of its 40,000-square foot research and development (R&D) facility in Harrisonburg, Virginia. SRI funded the $2.8 million build-out to further advance its bioscience research capabilities at SRI's Shenandoah Valley (SRI SV) Center for Advanced Drug Research. SRI has also renewed its five-year lease in the Innovation Village at Rockingham, reaffirming its commitment to the region.

SRI's new biomedical facilities include more than 2,500-square feet of laboratory and storage areas for preclinical research, drug discovery, and drug development programs to support growing client and partner needs. R&D at SRI Shenandoah Valley focuses on basic research, including emerging infectious diseases, metabolic diseases, and proteomics; therapeutic discovery and development of drugs, vaccines and biologics; and personalized medicine, such as companion diagnostics and biomarkers.

As part of SRI's growth, renowned experts have joined the SRI Biosciences team. New hires at SRI Shenandoah Valley include:

  • Thomas Voss, Ph.D., Director of Virology, Center for Immunology and Infectious Diseases: Voss' research interests include cell-virus interactions and their role in acute viral infections, as well as therapeutic drug and vaccine development. At SRI, he is continuing his research on new models for developing treatments for influenza and other infectious diseases. He joined SRI from the faculty of Tulane School of Medicine's Department of Microbiology and Immunology. Earlier, he worked in various roles at Southern Research Institute, ultimately as vice president of the Homeland Security and Emerging Infectious Disease Division.
  • Tianyi "Tony" Wang, Ph.D., Senior Scientist, Virology, Center for Immunology and Infectious Diseases: Wang studies the entry mechanism of Hepatitis C virus (HCV) and natural immunity against viruses. His current research includes characterizing the role of the occludin protein in HCV entry and how HCV infection alters the physiology of tight junctions, the areas between cells where membranes join together. Prior to joining SRI, Wang was a faculty member in the University of Pittsburgh's Department of Infectious Diseases and Microbiology.
  • Lynn Chellarajan, Laboratory Supervisor: Chellarajan is the operational manager of SRI's new SRI SV preclinical laboratories and oversees the daily operation of a broad range of toxicology and pharmacology studies conducted to advance promising therapeutics from the discovery stage towards human clinical trials. Prior to joining SRI, she spent more than a decade working in the pharmaceutical industry at PharmaMar USA, Millennium, and Eisai. Chellarajan is actively recruiting additional staff to support SRI's expanding preclinical activities.

"In 2007, a small number of SRI colleagues and I first began working in a laboratory on the campus of James Madison University, which marked the founding of our Center for Advanced Drug Research in Shenandoah Valley. Since then, due in large part to the support of the Commonwealth of Virginia and other regional partners, we have grown and established a state-of-the-art facility tackling the challenges of drug discovery and development for critical and emerging diseases," said Krishna Kodukula, Ph.D., executive director, strategic development and site head of SRI Shenandoah Valley. "Tom Voss, Tony Wang, and Lynn Chellarajan, the most recent staff members to join our team from around the world, are valuable assets in SRI's expanded research capabilities."

SRI's successful growth in Shenandoah Valley has also been demonstrated through regional innovation programs and spin-off companies that have resulted from SRI research and development. Regional and local start-ups include Redcoat Solutions, Inc. and RioGin. Redcoat will soon launch bed bug detection products into commercial and consumer markets. The products will allow users to quickly determine when a room is infested with bed bugs before obvious signs of infestation are visible. RioGin is researching a technology to reduce side effects and improve the efficacy of peptide drugs.

SRI SV is located on 25 acres in the Innovation Village at Rockingham, a 325-acre development less than two hours from Washington, D.C., and other mid-Atlantic cities.

About SRI Biosciences
SRI Biosciences carries out basic research, drug discovery, and drug development. SRI has all of the resources necessary to take R&D from initial discoveries to clinical trials. SRI's product pipeline has yielded marketed drugs, therapeutics currently in human testing, and additional programs at earlier stages. SRI Biosciences offers a wide range of contract research organization (CRO) services, helping government and industry clients and partners advance drugs and other biomedical products toward commercialization. SRI is also working to create the next generation of technologies in areas such as diagnostics, drug delivery, medical devices, and systems biology.

About SRI International
Innovations from SRI International have created new industries, billions of dollars of marketplace value, and lasting benefits to society—touching our lives every day. SRI, a nonprofit research and development institute based in Silicon Valley, brings its innovations to the marketplace through technology licensing, new products, and spin-off ventures. Government and business clients come to SRI for pioneering R&D and solutions in computing and communications, chemistry and materials, education, energy, health and pharmaceuticals, national defense, robotics, sensing, and more.
Visit SRI's website and Timeline of Innovation to learn more about SRI.

SOURCE SRI International
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Biocartis Presents the Successful use of Idylla[TM] for the Detection of the BRAF Mutation Status in Tumour Samples at the International AACR Congress (American Association for Cancer Research) in Boston
2. 3-V Biosciences Presents Positive Data for Novel FASN Inhibitor at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
3. Dyadic International Extends All Debt Maturity Dates
4. Improving Outcomes in the Treatment and Management of Metastatic Colorectal Cancer - International White Paper Launched at European Cancer Congress 2013
5. Mylan Supports Generic Drug Industrys Call on FDA to Uphold Consistent, Proven International Standard for Biosimilar Naming
6. CIVCO Names Darrell Newcombe as Vice President of International Sales for Radiation Oncology
7. Paul Kauffman of Accident Fund to Present on Identifying Risky Opioid Prescribing Patterns at 99th Annual International Association of Industrial Accident Boards & Commissions Conference
8. Multiple International Breast Cancer Guidelines Confirm Use of Agendia Tests for Prognostic, Predictive Information in Cancer Treatment Decisions
9. Metabolic Solutions Development Company presents Phase 2a clinical trial results at the 14th International Conference on Alzheimers Drug Discovery
10. WIKA Process Solutions, Deer Park, Texas Acquires Gayesco International.
11. PAREXEL International To Present At Robert Baird Healthcare Conference And Raymond James North American Equities Conference
Post Your Comments:
(Date:11/27/2015)... ) ... "2016 Global Tumor Marker Testing Market: Supplier ... Segment Forecasts, Innovative Technologies, Instrumentation Review, Competitive ... offering. --> ) has ... Global Tumor Marker Testing Market: Supplier Shares ...
(Date:11/26/2015)... , Países Bajos, November 26, 2015 ... terapia fotodinámica de Bremachlorin para el cáncer avanzado. ... inmunoterapia con la terapia fotodinámica de Bremachlorin para el ... nuevo enfoque combina la inmunoterapia con la terapia fotodinámica ... Clinical Cancer Research . --> Clinical ...
(Date:11/26/2015)... , November 26, 2015 ... new combination approach blends immunotherapy with Bremachlorin-photodynamic therapy for ... combination approach blends immunotherapy with Bremachlorin-photodynamic therapy for advanced ... combination approach blends immunotherapy with Bremachlorin-photodynamic therapy for advanced ... has found that immunotherapy can be efficiently combined ...
Breaking Medicine Technology:
(Date:11/27/2015)... , ... November 27, 2015 , ... Avid collector, Andrew ... Arbor Michigan boxing style concert posters. This is one of Joplin's most famous and ... House at the University of Michigan in Ann Arbor. The According to Hawley, "It ...
(Date:11/26/2015)... ... November 26, 2015 , ... Inevitably when people think Thanksgiving, they also ... buy during the Black Friday and Cyber Monday massage chair sales to ... Internet high and low to find the best massage chair deals, they can see ...
(Date:11/26/2015)... (PRWEB) , ... November 26, 2015 , ... ... of workshops to discuss bioavailability and the need to integrate dose form selection ... in collaboration with OBN, the membership organization supporting and bringing together the UK’s ...
(Date:11/26/2015)... ... November 26, 2015 , ... WorldCare International, ... in the 61st annual Employee Benefits Conference. The Employee Benefits Conference was hosted ... 8th through Wednesday, November 11th, 2015. The conference was held at the Hawaii ...
(Date:11/26/2015)... ... 2015 , ... Indosoft Inc., developer and distributor of the world-class Asterisk based ... efficiency and reliability. , The new Q-Suite 6 platform is based on the latest ... itself into a specific piece of software for many key components of the suite. ...
Breaking Medicine News(10 mins):